Theratechnologies Obtains U.S. Patent Term Extension for Tesamorelin

MONTREAL, QUEBEC--(Marketwired - June 9, 2014) - Theratechnologies Inc. (TSX:TH) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent term extension certificate for tesamorelin, the Company's principal compound. Pursuant to this certificate, the USPTO has extended the term of US patent No. 5,861,379 (tesamorelin composition of matter patent) by five years. This patent was originally set to expire in May 2015 and is now set to expire in May 2020.

"We are happy to see that the determination made by the USPTO in granting a five-year term extension is the same as the one we made when we applied for this patent term extension more than three years ago. The combination of this five-year term extension on our main patent with our patents covering the use of tesamorelin for the treatment of HIV-associated lipodystrophy set to expire in 2023 should add value to our EGRIFTA^® asset and benefit our shareholders", said Mr. Luc Tanguay, President and CEO, Theratechnologies Inc.

About Theratechnologies

Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and improved quality of life. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on the SEC's website at www.sec.gov.

Forward-Looking Information

This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation, which statements may contain such words as "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions. This forward-looking information includes, but is not limited to, information regarding the enhancement of value to the Company's asset.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but are not limited to, the fact that the patents owned by Theratechnologies will not be challenged by a third party and, if challenged, Theratechnologies will be able to adequately defend and sustain the validity of its patents and the fact that Theratechnologies will be able to commercialize and sell EGRIFTA^® until the expiry of its patents covering such product. These risks and uncertainties include, but are not limited to, the risk that Theratechnologies' patents are challenged and held to be invalid or unenforceable.

We refer potential investors to the "Risk Factors" section of our Annual Report on Form 20-F dated February 27, 2014 available at www.sedar.com, www.sec.gov and www.theratech.com. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.